Clinical trials
Recurrent Malignant Solid Neoplasm clinical trials
Below are recruiting recurrent malignant solid neoplasm clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05059678Recruiting
Parenting support for families facing advanced cancer
This study tests a program to help parents with advanced cancer support their children and manage family life during treatment. It may help you feel more confident as a parent while coping with cancer.
Houston, TexasAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Baltimore, MarylandAges 18 years+ - NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
Birmingham, AlabamaAges 2 months+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Birmingham, AlabamaAges Up to 25 years - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT01050504Recruiting
Donate blood and tissue to study recurrent or metastatic cancers
This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.
Seattle, WashingtonAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Los Angeles, CaliforniaAges 1 month–17 years
Hear when a new Recurrent Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent malignant solid neoplasm?
- Yes. Clin2 currently lists 64 recruiting recurrent malignant solid neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent malignant solid neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.